Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Phase 1

Terminated

Conditions: Advanced Cancers

Interventions: Drug: Temsirolimus

First Posted Date: 2009-04-08

Last Posted Date: 2016-08-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT00877773

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Temsirolimus

First Posted Date: 2009-02-09

Last Posted Date: 2024-07-10

Lead Sponsor: Loyola University

Target Recruit Count: 14

Registration Number: NCT00838955

Locations: 🇺🇸
Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Malignant Carcinoma

Interventions: Drug: Neratinib
Drug: Temsirolimus

First Posted Date: 2009-02-06

Last Posted Date: 2018-09-18

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 63

Registration Number: NCT00838539

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 1 locations

Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Temsirolimus
Drug: Irinotecan

First Posted Date: 2009-01-23

Last Posted Date: 2011-06-08

Lead Sponsor: Vejle Hospital

Target Recruit Count: 50

Registration Number: NCT00827684

Locations: 🇩🇰
Vejle Hospital, Dept. of Oncology, Vejle, Denmark
🇩🇰
Rigshospitalet, Department of Oncology, Copenhagen, Denmark

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Temsirolimus
Drug: Irinotecan
Procedure: Surgical Resection of Primary Tumor
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Drug: Cisplatin
Drug: Topotecan
Procedure: PBSC
Radiation: Radiation Therapy
Drug: 13-cis-retinoic acid

First Posted Date: 2008-12-16

Last Posted Date: 2017-05-30

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT00808899

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme

First Posted Date: 2008-12-02

Last Posted Date: 2010-06-02

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 12

Registration Number: NCT00800917

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark

Temsirolimus and Radiation for Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Temsirolimus
Radiation: Radiation therapy

First Posted Date: 2008-11-24

Last Posted Date: 2013-07-11

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 10

Registration Number: NCT00796796

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2008-11-11

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00788580

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cladribine
Drug: temsirolimus
Biological: Filgrastim
Biological: Pegfilgrastim

First Posted Date: 2008-11-10

Last Posted Date: 2018-01-09

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 74

Registration Number: NCT00787969

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸
St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States

and more 141 locations

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Metastatic Cancer

Interventions: Other: cytokine levels
Drug: temsirolimus
Other: pharmacological study

First Posted Date: 2008-11-04

Last Posted Date: 2018-04-17

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 12

Registration Number: NCT00784914

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy